Raymond James Biotech Innovation Symposium: Dyne's CEO John Cox shares an overview of the company's recent landmark DMD data

He describes both the biomarker and functional benefits seen in the December data for the company's next-generation exon 51 skipping therapy.

Episode metadata supplied by the publisher feed · Published Apr 14, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Raymond James Biotech Innovation Symposium: Dyne's CEO John Cox shares an overview of the company's recent landmark DMD data

0:00 12:58

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Similar Episodes

No similar episodes found.

No similar podcasts found.

This episode is 12 minutes long.

This episode was published on April 14, 2026.

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!